Perspective from Rishi P. Singh, MD
Source/Disclosures
Source:

Lu AJ, et al. Ophthalmic Surg Lasers Imaging Retina. 2019;doi:10.3928/23258160-20190129-06.

March 04, 2019
1 min read
Save

Patient, systemic barriers impede follow-up for diabetic retinopathy

Perspective from Rishi P. Singh, MD
Source/Disclosures
Source:

Lu AJ, et al. Ophthalmic Surg Lasers Imaging Retina. 2019;doi:10.3928/23258160-20190129-06.

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Patients who did not attend follow-up appointments for their diabetic retinopathy were more likely to have other medical conditions or to forget they have an appointment, according to a study.

“Understanding the patient-reported barriers to compliance with appointments for diabetic retinopathy is critical to improving treatment for this disease. We found that patients reported having other medical conditions to care for as well as forgetting their appointments as the major reasons for lack of follow-up,” study co-author Daniel L. Chao, MD, PhD, told Healio.com/OSN.

Chao and colleagues conducted a 21-question survey of 209 eligible patients with diabetic retinopathy to identify barriers to attending follow-up appointments. Forty-six percent of patients cited long waiting times in clinics, 35.9% reported other medical/physical conditions, 28.2% reported forgetting, and 9.1% reported inability to leave work. In a univariate model, both “other medical or physical condition” and “forgot to come” were found to be independent risk factors for noncompliance with follow-up.

Patients noted providing reminders of appointments and mobile van pick-up could help improve compliance for follow-up care.

“This information may help drive interventions to improve compliance for follow-up for patients with diabetic retinopathy,” Chao said. – by Robert Linnehan

Disclosure: Chao reports he is a consultant for Allergan.